维生素C、硫胺素与氢化可的松对脓毒症患者无呼吸机及无升压药天数的影响:VICTAS随机临床试验
VICTAS多中心随机双盲安慰剂对照试验纳入501例脓毒症所致呼吸和/或心血管功能障碍成人患者,比较每6小时静脉给予维生素C 1.5g、硫胺素100mg与氢化可的松50mg联合治疗与安慰剂。结果显示两组30天内无呼吸机及无升压药天数中位数分别为25天与26天,差异无统计学意义;30天死亡率分别为22%与24%。试验因行政原因提前终止,可能把握度不足。
要点
- 维生素C+硫胺素+氢化可的松联合方案未显著增加脓毒症患者30天内无呼吸机及无升压药天数。
- 干预组与安慰剂组30天死亡率分别为22%与24%,无显著差异。
- 试验因行政原因提前终止,可能不足以检测临床重要差异。
核心结论
- 在脓毒症危重患者中,与安慰剂相比,维生素C、硫胺素和氢化可的松联合治疗未显著增加30天内无呼吸机及无升压药天数。
- 试验因行政原因提前终止,可能把握度不足,无法检测临床重要差异。
研究设计与样本
- 多中心、随机、双盲、适应性样本量、安慰剂对照试验,在美国43家医院的急诊科或ICU进行。
- 2018年8月至2019年7月纳入501例脓毒症所致呼吸和/或心血管功能障碍成人患者,随机分配至干预组(n=252)或安慰剂组(n=249)。
- 干预为每6小时静脉给予维生素C 1.5g、硫胺素100mg和氢化可的松50mg,持续96小时或直至ICU出院或死亡;安慰剂组给予匹配安慰剂。
- 临床团队可给予开放标签糖皮质激素,若每日总剂量≥氢化可的松等效200mg,则暂停研究药物。
- 主要结局为随机化后30天内连续无呼吸机及无升压药天数;关键次要结局为30天死亡率。
主要发现
- 干预组30天死亡率为22%,安慰剂组为24%。
- 干预组和对照组分别有33%和32%的患者接受了开放标签糖皮质激素治疗。
临床怎么用
- 对于脓毒症所致呼吸和/或心血管功能障碍的危重患者,不建议常规使用维生素C、硫胺素和氢化可的松联合方案来增加无呼吸机及无升压药天数。
- 临床决策时应考虑该试验因提前终止可能把握度不足,阴性结果需谨慎解读。
局限性
- 试验在纳入501例参与者后因资金撤回而行政终止,可能把握度不足。
- 干预组和对照组分别有33%和32%的患者接受开放标签糖皮质激素,可能影响结果。
- 研究仅在美国43家医院进行,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment for patients with sepsis. OBJECTIVE: To determine whether a combination of vitamin C, thiamine, and hydrocortisone every 6 hours increases ventilator- and vasopressor-free days compared with placebo in patients with sepsis. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted in adult patients with sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled in the emergency departments or intensive care units at 43 hospitals in the United States between August 2018 and July 2019. After enrollment of 501 participants, funding was withheld, leading to an administrative termination of the trial. All study-related follow-up was completed by January 2020. INTERVENTIONS: Participants were randomized to receive intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n = 252) or matching placebo (n = 249) for 96 hours or until discharge from the intensive care unit or death. Participants could be treated with open-label corticosteroids by the clinical team, with study hydrocortisone or matching placebo withheld if the total daily dose was greater or equal to the equivalent of 200 mg of hydrocortisone. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of consecutive ventilator- and vasopressor-free days in the first 30 days following the day of randomization. The key secondary outcome was 30-day mortality. RESULTS: Among 501 participants randomized (median age, 62 [interquartile range {IQR}, 50-70] years; 46% female; 30% Black; median Acute Physiology and Chronic Health Evaluation II score, 27 [IQR, 20.8-33.0]; median Sequential Organ Failure Assessment score, 9 [IQR, 7-12]), all completed the trial. Open-label corticosteroids were prescribed to 33% and 32% of the intervention and control groups, respectively. Ventilator- and vasopressor-free days were a median of 25 days (IQR, 0-29 days) in the intervention group and 26 days (IQR, 0-28 days) in the placebo group, with a median difference of -1 day (95% CI, -4 to 2 days; P = .85). Thirty-day mortality was 22% in the intervention group and 24% in the placebo group. CONCLUSIONS AND RELEVANCE: Among critically ill patients with sepsis, treatment with vitamin C, thiamine, and hydrocortisone, compared with placebo, did not significantly increase ventilator- and vasopressor-free days within 30 days. However, the trial was terminated early for administrative reasons and may have been underpowered to detect a clinically important difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03509350.
引用
- Sevransky JE, Rothman RE, Hager DN, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. JAMA. 2021. PMID: 33620405. doi:10.1001/jama.2020.24505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。